i agree with a lot of what you say, and you have a very balanced view.
i think the forced index buying is a bit of a lack of research on your part however, and also what had transpired to have the MC staying below 300m.
cu6 raised in March 2024 @2.55, they only just got included in the all ordinaries in March @2.69. Before the raise, they probably sat around 260-290m SOI fully diluted, so were sitting around 600-700m MC.
to say it should stay in the 300m MC range because it only went up after getting included in the 200-300index seems inconsistent with transpired events. I think there isn't a lot of significance with getting included in the all ords.
investors seem to have a short memory for buyouts and what they sold for and at what phase of clinical trials. But looking at the wider global biotech market, it seems the same across the board.
i agree that a raise and getting kicked out of other index will happen, and what may continue to dampen the stock, unless news out of the blue happens.
CU6 Price at posting:
$2.22 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)